Key result
A nickel-albumin binding assay (NABA) presented a higher ability to discriminate myocardial ischaemia than a cobalt-albumin binding assay (CABA).
Why the study?
Does a nickel-albumin binding assay (NABA) improve the discrimination of myocardial ischaemia compared to a cobalt-albumin binding assay (CABA) in patients presenting with chest pain?
Observational (n=96)
Does a nickel-albumin binding assay (NABA) improve the discrimination of myocardial ischaemia compared to a cobalt-albumin binding assay (CABA) in patients presenting with chest pain?
The nickel-albumin binding assay (NABA) demonstrates superior ability to discriminate myocardial ischemia compared to the traditional cobalt-albumin binding assay, suggesting potential utility as an early ischemic biomarker.
NABA may discriminate myocardial ischemia better than CABA in chest pain; hypothesis-generating and requires prospective validation before any clinical adoption.
BACKGROUND: The aim of this study was to describe a method to measure ischaemia-induced alterations of the binding capacity of serum albumin to exogenous nickel. METHODS: We measured the levels of cardiac troponin I (cTnI), serum albumin, ischaemia-modified albumin (IMA) measured by a cobalt-albumin binding assay (CABA), and a nickel-albumin binding assay (NABA) in the following groups: myocardial infarction (n = 32) and non-ischaemic chest pain (n = 64). RESULTS: IMA, cTnI and NABA levels were higher in the myocardial infarction group. NABA presented a higher ability to discriminate myocardial ischaemia than CABA. CONCLUSIONS: Patients with myocardial infarction have reduced nickel binding to human serum albumin, and NABA may have an important role as an early marker of myocardial ischaemia.
No takes yet. Share an insight, caveat, or question.
Silva et al. (2010) conducted an observational in Myocardial ischaemia (n=96). Nickel-albumin binding assay (NABA) vs. Cobalt-albumin binding assay (CABA) was evaluated on Discrimination of myocardial ischaemia. A nickel-albumin binding assay (NABA) presented a higher ability to discriminate myocardial ischaemia than a cobalt-albumin binding assay (CABA).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: